Man Group PLC Lineage Cell Therapeutics, Inc. Transaction History

Man Group PLC

  • $38.1 Billion
  • Q1 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$1.2 - $1.53 $3,224 - $4,111
-2,687 Reduced 2.62%
99,709 $149,000
Q4 2022

Feb 14, 2023
BUY
$1.02 - $1.5 $104,443 - $153,594
102,396 New
102,396 $119,000
Q1 2021

May 17, 2021
SELL
$1.77 - $3.1 $42,104 - $73,742
-23,788 Closed
0 $0
Q4 2020

Feb 16, 2021
BUY
$0.95 - $1.83 $22,598 - $43,532
23,788 New
23,788 $42,000

Others Institutions Holding LCTX

# of Institutions
124
Shares Held
93.5M
Call Options Held
21.4K
Put Options Held
0
View Full List

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $158M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email